Alnylam Set For Transformation As Patisiran Nears Market With Data Upgrade

25 Apr 2018

• By John Davis

Alnylam has outlined further data and analyses from the Phase III APOLLO study supporting the use of its selective interfering RNA agent, patisiran, as it nears the market for the treatment of hATTR amyloidosis.

Rocket — Alnylam's lead product has been submitted for marketing approval • Source: Shutterstock

At the start of 2018, Alnylam Pharmaceuticals Inc. regained rights previously licensed to Sanofi on its lead product, patisiran, and the US biotech has now added to the growing excitement surrounding this new class of small interfering RNA (siRNA) agents by reporting positive all-cause hospitalization and mortality data from a post-hoc analysis of the APOLLO Phase III study.

The analysis builds on previously reported data from APOLLO that showed patisiran halted or reversed neuropathy progression in the majority of patients treated with the RNAi therapeutic for hereditary ATTR...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.